Metabolism & weight

GLP-1 receptor agonist — approved, prescription-only.

Also known as: Ozempic, Wegovy, Rybelsus

Dual GIP/GLP-1 receptor agonist — approved, prescription-only.

Also known as: Mounjaro, Zepbound

Triple agonist (GIP/GLP-1/glucagon) — in clinical testing, NOT approved.

Also known as: LY3437943

HGH fragment — clinically investigated, but not approved as a weight-loss medication.

Also known as: HGH-Fragment 176-191, Anti-Obesity Drug 9604

GHRH analogue — approved prescription-only in the USA (HIV lipodystrophy).

Also known as: Egrifta

Not a peptide but an NNMT inhibitor — fat-metabolism research without human data.

Also known as: 5-Amino-1-Methylquinolinium, NNMT-Inhibitor

Approved, prescription-only GLP-1 receptor agonist for type 2 diabetes and obesity – a predecessor of semaglutide and not a substance for self-administration.

Also known as: Victoza, Saxenda, Liraglutide

Long-acting GLP-1 receptor agonist (Fc fusion protein), once weekly – an approved prescription diabetes medication.

Also known as: Trulicity, LY2189265, Dulaglutide

Synthetic exendin-4: the first approved GLP-1 receptor agonist — originally derived from the saliva of the Gila monster.

Also known as: Byetta, Bydureon, Bydureon BCise

Long-acting amylin analogue in clinical investigation for weight regulation – not approved.

Also known as: Cagrilintide, AM833, NNC0174-0833

Experimental dual GLP-1/glucagon receptor agonist – in clinical trials for obesity and MASH, not approved anywhere.

Also known as: BI 456906, Survodutide (INN)

Dual GLP-1/glucagon receptor agonist (oxyntomodulin analog), approved in China, under investigation elsewhere

Also known as: Mazdutide, IBI362, LY3305677

Experimenteller GLP-1- und Amylin-Rezeptoragonist in einem einzigen Molekül - Phase 3, nicht zugelassen.

Also known as: NN9487, NNC0487-0111, Amycretin (Novo Nordisk)

Erster oraler PCSK9-Hemmer als Tablette – makrozyklisches Peptid zur LDL-Cholesterin-Senkung.

Also known as: Lipfendra, MK-0616, Enlicitide decanoate

Monatlicher Studienwirkstoff von Amgen gegen Adipositas — GLP-1-Agonismus plus GIP-Rezeptor-Blockade, noch ohne Zulassung.

Also known as: MariTide, AMG 133, Maridebart cafraglutide

Der prominenteste Tirzepatid-Herausforderer außerhalb von Lilly und Novo – dual auf GLP-1 und GIP, in Phase 3, aber noch nirgends zugelassen.

Also known as: VK2735, VK-2735

Untersuchter, balancierter Glukagon-/GLP-1-Doppelagonist mit Schwerpunkt Leber (MASH) – nicht zugelassen.

Also known as: Pemvidutide, ALT-801, ALT801

Fixkombination aus zwei injizierbaren Peptiden — dem Amylin-Analogon Cagrilintid und dem GLP-1-Agonisten Semaglutid — zur Gewichtsreduktion; Phase 3 abgeschlossen, Zulassungsantrag eingereicht, noch nicht zugelassen.

Also known as: Cagrilintid/Semaglutid-Fixkombination, Cagrilintide/Semaglutide, CagriSema (Novo Nordisk)

Langwirksamer Amylin-Analog in Phase 3 – zweistelliger Gewichtsverlust bei nahezu placeboähnlicher Magen-Darm-Verträglichkeit (nicht zugelassen).

Also known as: Petrelintide, ZP8396, Petrelintid (Roche/Zealand)